{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:40:08Z","timestamp":1785580808239,"version":"3.56.0"},"reference-count":44,"publisher":"National Institute for Health and Care Research","issue":"38","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["08\/56\/04"],"award-info":[{"award-number":["08\/56\/04"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\">\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Anti-neutrophil cytoplasm antibody-associated vasculitis is a multisystem, autoimmune disease that causes organ failure and death. Physical removal of pathogenic autoantibodies by plasma exchange is recommended for severe presentations, along with high-dose glucocorticoids, but glucocorticoid toxicity contributes to morbidity and mortality. The lack of a robust evidence base to guide the use of plasma exchange and glucocorticoid dosing contributes to variation in practice and suboptimal outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"abs1-2\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We aimed to determine the clinical efficacy of plasma exchange in addition to immunosuppressive therapy and glucocorticoids with respect to death and end-stage renal disease in patients with severe anti-neutrophil cytoplasm antibody-associated vasculitis. We also aimed to determine whether or not a reduced-dose glucocorticoid regimen was non-inferior to a standard-dose regimen with respect to death and end-stage renal disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"abs1-3\">\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>This was an international, multicentre, open-label, randomised controlled trial. Patients were randomised in a two-by-two factorial design to receive either adjunctive plasma exchange or no plasma exchange, and either a reduced or a standard glucocorticoid dosing regimen. All patients received immunosuppressive induction therapy with cyclophosphamide or rituximab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"abs1-4\">\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Ninety-five hospitals in Europe, North America, Australia\/New Zealand and Japan participated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"abs1-5\">\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>Participants were aged \u2265\u200916 years with a diagnosis of granulomatosis with polyangiitis or microscopic polyangiitis, and either proteinase 3 anti-neutrophil cytoplasm antibody or myeloperoxidase anti-neutrophil cytoplasm antibody positivity, and a glomerular filtration rate of &lt;\u200950\u2009ml\/minute\/1.73\u2009m<jats:sup>2<\/jats:sup> or diffuse alveolar haemorrhage attributable to active anti-neutrophil cytoplasm antibody-associated vasculitis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"abs1-6\">\n                  <jats:title>Interventions<\/jats:title>\n                  <jats:p>Participants received seven sessions of plasma exchange within 14 days or no plasma exchange. Oral glucocorticoids commenced with prednisolone 1\u2009mg\/kg\/day and were reduced over different lengths of time to 5\u2009mg\/kg\/day, such that cumulative oral glucocorticoid exposure in the first 6 months was 50% lower in patients allocated to the reduced-dose regimen than in those allocated to the standard-dose regimen. All patients received the same glucocorticoid dosing from 6 to 12 months. Subsequent dosing was at the discretion of the treating physician.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"abs1-7\">\n                  <jats:title>Primary outcome<\/jats:title>\n                  <jats:p>The primary outcome was a composite of all-cause mortality and end-stage renal disease at a common close-out when the last patient had completed 10 months in the trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"abs1-8\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study recruited 704 patients from June 2010 to September 2016. Ninety-nine patients died and 138 developed end-stage renal disease, with the primary end point occurring in 209 out of 704 (29.7%) patients: 100 out of 352 (28%) in the plasma exchange group and 109 out of 352 (31%) in the no plasma exchange group (adjusted hazard ratio 0.86, 95% confidence interval 0.65 to 1.13; <jats:italic>p<\/jats:italic>\u2009=\u20090.3). In the per-protocol analysis for the non-inferiority glucocorticoid comparison, the primary end point occurred in 92 out of 330 (28%) patients in the reduced-dose group and 83 out of 325 (26%) patients in the standard-dose group (partial-adjusted risk difference 0.023, 95% confidence interval 0.034 to 0.08; <jats:italic>p<\/jats:italic>\u2009=\u20090.5), thus meeting our non-inferiority hypothesis. Serious infections in the first year occurred in 96 out of 353 (27%) patients in the reduced-dose group and in 116 out of 351 (33%) patients in the standard-dose group. The rate of serious infections at 1 year was lower in the reduced-dose group than in the standard-dose group (incidence rate ratio 0.69, 95% confidence interval 0.52 to 0.93; <jats:italic>p<\/jats:italic>\u2009=\u20090.016).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"abs1-9\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Plasma exchange did not prolong the time to death and\/or end-stage renal disease in patients with anti-neutrophil cytoplasm antibody-associated vasculitis with severe renal or pulmonary involvement. A reduced-dose glucocorticoid regimen was non-inferior to a standard-dose regimen and was associated with fewer serious infections.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"abs1-10\">\n                  <jats:title>Future work<\/jats:title>\n                  <jats:p>A meta-analysis examining the effects of plasma exchange on kidney outcomes in anti-neutrophil cytoplasm antibody-associated vasculitis is planned. A health-economic analysis of data collected in this study to examine the impact of both plasma exchange and reduced glucocorticoid dosing is planned to address the utility of plasma exchange for reducing early end-stage renal disease rates. Blood and tissue samples collected in the study will be examined to identify predictors of response to plasma exchange in anti-neutrophil cytoplasm in antibody-associated vasculitis. The benefits associated with reduced glucocorticoid dosing will inform future studies of newer therapies to permit further reduction in glucocorticoid exposure. Data from this study will contribute to updated management recommendations for anti-neutrophil cytoplasm antibody-associated vasculitis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"abs1-11\">\n                  <jats:title>Limitations<\/jats:title>\n                  <jats:p>This study had an open-label design which may have permitted observer bias; however, the nature of the end points, end-stage renal disease and death, would have minimised this risk. Despite being, to our knowledge, the largest ever trial in anti-neutrophil cytoplasm antibody-associated vasculitis, there was an insufficient sample size to assess clinically useful benefits on the separate components of the primary end-point: end-stage renal disease and death. Use of a fixed-dose plasma exchange regimen determined by consensus rather than data-driven dose ranging meant that some patients may have been underdosed, thus reducing the therapeutic impact. In particular, no biomarkers have been identified to help determine dosing in a particular patient, although this is one of the goals of the biomarker plan of this study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"abs1-12\">\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>This trial is registered as ISRCTN07757494, EudraCT 2009-013220-24 and Clinicaltrials.gov NCT00987389.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"abs1-13\">\n                  <jats:title>Funding<\/jats:title>\n                  <jats:p>This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in <jats:italic>Health Technology Assessment<\/jats:italic>; Vol. 26, No. 38. See the NIHR Journals Library website for further project information.<\/jats:p>\n               <\/jats:sec>","DOI":"10.3310\/pnxb5040","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T08:43:11Z","timestamp":1664181791000},"page":"1-60","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT"],"prefix":"10.3310","volume":"26","clinical-trial-number":[{"clinical-trial-number":"isrctn07757494","registry":"10.18810\/isrctn","type":"results"},{"clinical-trial-number":"2009-013220-24","registry":"10.18810\/euctr","type":"results"},{"clinical-trial-number":"nct00987389","registry":"10.18810\/clinical-trials-gov","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-0637","authenticated-orcid":true,"given":"David","family":"Jayne","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8292-2014","authenticated-orcid":true,"given":"Michael","family":"Walsh","sequence":"additional","affiliation":[{"name":"Department of Nephrology, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-7345","authenticated-orcid":true,"given":"Peter A","family":"Merkel","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9712-0396","authenticated-orcid":true,"given":"Chen Au","family":"Peh","sequence":"additional","affiliation":[{"name":"Royal Adelaide Hospital, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6570-6077","authenticated-orcid":true,"given":"Wladimir","family":"Szpirt","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3573-9203","authenticated-orcid":true,"given":"Xavier","family":"Pu\u00e9chal","sequence":"additional","affiliation":[{"name":"National Referral Centre for Rare Systemic Autoimmune Diseases, Cochin Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2854-8169","authenticated-orcid":true,"given":"Shouichi","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Hemovascular Medicine and Artificial Organs, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1392-5649","authenticated-orcid":true,"given":"Carmel","family":"Hawley","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The University of Queensland, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8270-2617","authenticated-orcid":true,"given":"Nader","family":"Khalidi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Jones","sequence":"additional","affiliation":[{"name":"Renal Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5976-3609","authenticated-orcid":true,"given":"Oliver","family":"Flossmann","sequence":"additional","affiliation":[{"name":"Renal Unit, Royal Berkshire Hospital, Reading, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4411-8169","authenticated-orcid":true,"given":"Ron","family":"Wald","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, St Michael\u2019s Hospital, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9044-008X","authenticated-orcid":true,"given":"Louis","family":"Girard","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2438-8401","authenticated-orcid":true,"given":"Adeera","family":"Levin","sequence":"additional","affiliation":[{"name":"Department of Nephrology, St Paul\u2019s Hospital, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8404-3862","authenticated-orcid":true,"given":"Gina","family":"Gregorini","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1343-9234","authenticated-orcid":true,"given":"Lorraine","family":"Harper","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3294-739X","authenticated-orcid":true,"given":"William","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University of Western Ontario, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6287-9549","authenticated-orcid":true,"given":"Christian","family":"Pagnoux","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6559-1206","authenticated-orcid":true,"given":"Ulrich","family":"Specks","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6814-4877","authenticated-orcid":true,"given":"Lucy","family":"Smyth","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Royal Devon and Exeter Hospital, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7152-3026","authenticated-orcid":true,"given":"Toshiko","family":"Ito-Ihara","sequence":"additional","affiliation":[{"name":"Clinical and Translational Research Centre, Kyoto Prefecture University of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7528-9230","authenticated-orcid":true,"given":"Janak","family":"de Zoysa","sequence":"additional","affiliation":[{"name":"Department of Nephrology, North Shore Hospital, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5060-5604","authenticated-orcid":true,"given":"Biljana","family":"Brezina","sequence":"additional","affiliation":[{"name":"Renal Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8889-092X","authenticated-orcid":true,"given":"Andrea","family":"Mazzetti","sequence":"additional","affiliation":[{"name":"The Research Institute, St Joseph\u2019s Healthcare, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0016-6866","authenticated-orcid":true,"given":"Carol A","family":"McAlear","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-9923","authenticated-orcid":true,"given":"Donna","family":"Reidlinger","sequence":"additional","affiliation":[{"name":"Australasian Kidney Trials Network, The University of Queensland, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7096-513X","authenticated-orcid":true,"given":"Samir","family":"Mehta","sequence":"additional","affiliation":[{"name":"Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1664-7541","authenticated-orcid":true,"given":"Natalie","family":"Ives","sequence":"additional","affiliation":[{"name":"Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0669-3085","authenticated-orcid":true,"given":"Elizabeth A","family":"Brettell","sequence":"additional","affiliation":[{"name":"Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7374-3700","authenticated-orcid":true,"given":"Hugh","family":"Jarrett","sequence":"additional","affiliation":[{"name":"Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0792-580X","authenticated-orcid":true,"given":"Keith","family":"Wheatley","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8464-4353","authenticated-orcid":true,"given":"Elizabeth","family":"Broadhurst","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5822-593X","authenticated-orcid":true,"given":"Alina","family":"Casian","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1424-3906","authenticated-orcid":true,"given":"Charles D","family":"Pusey","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2022,9]]},"reference":[{"key":"key20220926093848841_ref1-bib1","article-title":"Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis: an international randomized controlled trial","author":"Jayne","year":"2009"},{"key":"key20220926093848841_ref1-bib2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S0049-0172(95)80015-8","article-title":"Epidemiology of systemic vasculitis: changing incidence or definition?","volume":"25","author":"Watts","year":"1995","journal-title":"Semin Arthritis Rheum"},{"key":"key20220926093848841_ref1-bib3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/0002-9343(67)90144-1","article-title":"Long-term follow-up study of periarteritis nodosa","volume":"43","author":"Frohnert","year":"1967","journal-title":"Am J Med"},{"key":"key20220926093848841_ref1-bib4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/ki.1992.377","article-title":"Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis","volume":"42","author":"Rota","year":"1992","journal-title":"Kidney Int"},{"key":"key20220926093848841_ref1-bib5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000063094","article-title":"Dose-related inhibition of proinflammatory cytokine release from neutrophils of the newborn by dexamethasone, betamethasone, and hydrocortisone","volume":"82","author":"Irakam","year":"2002","journal-title":"Biol Neonate"},{"key":"key20220926093848841_ref1-bib6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0002-9343(94)90131-7","article-title":"Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events","volume":"96","author":"Saag","year":"1994","journal-title":"Am J Med"},{"key":"key20220926093848841_ref1-bib7","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/art.21568","article-title":"Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy","volume":"54","author":"Wolfe","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key20220926093848841_ref1-bib8","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S0272-6386(03)00025-8","article-title":"Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study","volume":"41","author":"Booth","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"key20220926093848841_ref1-bib9","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1002\/1529-0131(200011)43:11<2481::AID-ANR15>3.0.CO;2-6","article-title":"Epidemiology of Wegener\u2019s granulomatosis in northern Norway","volume":"43","author":"Koldingsnes","year":"2000","journal-title":"Arthritis Rheum"},{"key":"key20220926093848841_ref1-bib10","doi-asserted-by":"publisher","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"De Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"key20220926093848841_ref1-bib11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"key":"key20220926093848841_ref1-bib12","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key20220926093848841_ref1-bib13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1745-6215-14-73","article-title":"Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial","volume":"14","author":"Walsh","year":"2013","journal-title":"Trials"},{"key":"key20220926093848841_ref1-bib14","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"key20220926093848841_ref1-bib15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0140-6736(77)91079-0","article-title":"Plasma-exchange and immunosuppression in the treatment of fulminating immune-complex crescentic nephritis","volume":"1","author":"Lockwood","year":"1977","journal-title":"Lancet"},{"key":"key20220926093848841_ref1-bib16","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1055\/s-2008-1070565","article-title":"Plasma exchange in rapidly progressive glomerulonephritis (author\u2019s transl)","volume":"106","author":"Gl\u00f6ckner","year":"1981","journal-title":"Dtsch Med Wochenschr"},{"key":"key20220926093848841_ref1-bib17","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/ki.1991.272","article-title":"Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies","volume":"40","author":"Pusey","year":"1991","journal-title":"Kidney Int"},{"key":"key20220926093848841_ref1-bib18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0272-6386(12)80699-8","article-title":"A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis: the Canadian Apheresis Study Group","volume":"20","author":"Cole","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"key20220926093848841_ref1-bib19","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1681\/ASN.2005080870","article-title":"Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement","volume":"17","author":"de Lind van Wijngaarden","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"key20220926093848841_ref1-bib20","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/jca.20035","article-title":"Apheresis for MPO-ANCA-associated RPGN-indications and efficacy: lessons learned from Japan nationwide survey of RPGN","volume":"20","author":"Yamagata","year":"2005","journal-title":"J Clin Apher"},{"key":"key20220926093848841_ref1-bib21","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1053\/j.ajkd.2010.10.049","article-title":"Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis","volume":"57","author":"Walsh","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"key20220926093848841_ref1-bib22","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1136\/bmj.1.5183.1399","article-title":"Treatment of polyarteritis nodosa with cortisone: results after three years: report to the Medical Research Council by the Collagen Diseases and Hypersensitivity Panel","volume":"1","author":"Pickering","year":"1960","journal-title":"Br Med J"},{"key":"key20220926093848841_ref1-bib23","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/ndt\/gfv060","article-title":"Twenty-five years of European Union collaboration in ANCA-associated vasculitis research","volume":"30","author":"Jayne","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"key20220926093848841_ref1-bib24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener\u2019s granulomatosis","volume":"352","author":"Wegener\u2019s Granulomatosis Etanercept Trial (WGET) Research Group","year":"2005","journal-title":"N Engl J Med"},{"key":"key20220926093848841_ref1-bib25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"key20220926093848841_ref1-bib26","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"key20220926093848841_ref1-bib27","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5","article-title":"A disease-specific activity index for Wegener\u2019s granulomatosis: modification of the Birmingham Vasculitis Activity Score: International Network for the Study of the Systemic Vasculitides (INSSYS)","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheum"},{"key":"key20220926093848841_ref1-bib28","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1002\/art.21117","article-title":"Damage caused by Wegener\u2019s granulomatosis and its treatment: prospective data from the Wegener\u2019s Granulomatosis Etanercept Trial (WGET)","volume":"52","author":"Seo","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key20220926093848841_ref1-bib29","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"key20220926093848841_ref1-bib30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000442323","article-title":"Overview of the pathogenesis of ANCA-associated vasculitis","volume":"1","author":"Xiao","year":"2016","journal-title":"Kidney Dis"},{"key":"key20220926093848841_ref1-bib31","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jama.295.10.1152","article-title":"Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement","volume":"295","author":"Piaggio","year":"2006","journal-title":"JAMA"},{"key":"key20220926093848841_ref1-bib32","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20220926093848841_ref1-bib33","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/ki.2013.131","article-title":"Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear","volume":"84","author":"Walsh","year":"2013","journal-title":"Kidney Int"},{"key":"key20220926093848841_ref1-bib34","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/ndt\/gfs428","article-title":"Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study","volume":"28","author":"Hilhorst","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"key20220926093848841_ref1-bib35","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/ndt\/gfq360","article-title":"Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener\u2019s granulomatosis \u2013 a clinical randomized controlled trial","volume":"26","author":"Szpirt","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"key20220926093848841_ref1-bib36","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/art.39562","article-title":"Diffuse alveolar hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis: predictors of respiratory failure and clinical outcomes","volume":"68","author":"Cartin-Ceba","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"key20220926093848841_ref1-bib37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1053\/ajkd.2002.29876","article-title":"Pulmonary renal syndrome: a 4-year, single-center experience","volume":"39","author":"Gallagher","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"key20220926093848841_ref1-bib38","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3109\/03009742.2012.754939","article-title":"Long-term outcome of severe alveolar haemorrhage in ANCA-associated vasculitis: a retrospective cohort study","volume":"42","author":"Hruskova","year":"2013","journal-title":"Scand J Rheumatol"},{"key":"key20220926093848841_ref1-bib39","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1055\/s-0031-1279830","article-title":"Management of alveolar hemorrhage in lung vasculitides","volume":"32","author":"Casian","year":"2011","journal-title":"Semin Respir Crit Care Med"},{"key":"key20220926093848841_ref1-bib40","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1172\/JCI15918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J Clin Invest"},{"key":"key20220926093848841_ref1-bib41","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ki.1992.194","article-title":"Association of IgM with IgG ANCA in patients presenting with pulmonary hemorrhage","volume":"41","author":"Esnault","year":"1992","journal-title":"Kidney Int"},{"key":"key20220926093848841_ref1-bib42","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/art.39011","article-title":"Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy","volume":"67","author":"Pagnoux","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20220926093848841_ref1-bib43","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1177\/0961203311418269","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis","volume":"20","author":"Zeher","year":"2011","journal-title":"Lupus"},{"key":"key20220926093848841_ref1-bib44","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","article-title":"Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis","volume":"76","author":"Miloslavsky","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2040315","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/PNXB5040\/PNXB5040.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2040315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:51:54Z","timestamp":1692114714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/PNXB5040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":44,"journal-issue":{"issue":"38","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["10.3310\/PNXB5040"],"URL":"https:\/\/doi.org\/10.3310\/pnxb5040","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"6-2009","name":"contractual_start_date","label":"Contractual start date","group":{"name":"article_history","label":"Article History"}},{"value":"12-2018","name":"editorial_review_begun","label":"Editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"8-2021","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}